[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-456319-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-456319-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","potential-role-of-imaging-in-the-evaluation-of-adiposity-and-approval-of-anti-obesity-drugs","Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs","","The review addresses the growing need for accurate body-composition assessment as obesity prevalence rises and treatment outcomes become harder to judge with conventional metrics. It compares imaging-based modalities—DXA, CT, MRI, and BIA—highlighting how each supports fat visualization, quantification, and distribution analysis. It emphasizes modality-specific strengths and constraints, including DXA accessibility, CT/MRI precision for visceral fat, and BIA variability, and links these methods to regulatory use of imaging endpoints in anti-obesity drug trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/potential-role-of-imaging-in-the-evaluation-of-adiposity-and-approval-of-anti-obesity-drugs/456319/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/potential-role-of-imaging-in-the-evaluation-of-adiposity-and-approval-of-anti-obesity-drugs/456319.png","ImageObject",300,407,{"name":42,"@type":43},"Fans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are imaging-based techniques important for evaluating obesity and adiposity?","Question",{"text":63,"@type":64},"Traditional measures like BMI and waist circumference cannot reliably quantify fat mass and distinguish it from lean mass. Imaging can visualize internal structures and enable more comprehensive fat assessment and treatment monitoring.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do DXA, CT, MRI, and BIA differ for fat quantification?",{"text":68,"@type":64},"DXA is cost-effective and suited for population-level screening, while CT and MRI provide higher precision, especially for visceral fat. BIA is practical and low-cost but limited by variability and lack of standardization.",{"name":70,"@type":61,"acceptedAnswer":71},"How do imaging endpoints support approval of anti-obesity drugs?",{"text":72,"@type":64},"Regulatory agencies such as the U.S. FDA and Korean MFDS increasingly recommend imaging data in clinical trials. These endpoints capture fat mass reduction beyond total weight loss, helping establish that weight loss is primarily attributable to fat reduction.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},456319,1791327135,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review Article | Technology, Experiment, and Physics  \neISSN 2005-8330  \n[https://doi.org/10.3348/kjr.2025.0937](https://doi.org/10.3348/kjr.2025.0937)  \n[Korean J Radiol 2026](Korean J Radiol 2026);[27](27)([1](1))[:48-62](:48-62)  \nPotential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs  \nSo Yeon Kim1 *, Sang Eun Won1 *, Hyo Jung Park1,2, ChangYun Woo3, Dong Wook Kim2, Chong Hyun Suh1,2, Kyung Won Kim1,2  \n1Asan Image Metrics, Clinical Trial Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea  \n2 Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea 3 Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea  \nThe global increase in obesity highlights the need for accurate tools to assess body composition and monitor treatment efficacy. Traditional metrics, including body mass index and waist circumference, offer limited precision for fat quantification. Imagingbased techniques capable of visualizing internal structures are increasingly being recognized for their ability to provide comprehensive fat assessment. This review outlines the principles, strengths, and limitations of key modalities, including dualenergy X-ray absorptiometry (DXA), CT, MRI, and bioelectrical impedance analysis (BIA). DXA is cost-effective and accessible for population-level screening, whereas CT and MRI offer higher precision, particularly for visceral fat assessment. BIA is a practical, low-cost alternative, but it is limited by variability and lack of standardization. Regulatory agencies, including the US Food and Drug Administration and the Korean Ministry of Food and Drug Safety, are increasingly supporting imaging-based endpoints in clinical trials of anti-obesity drugs because these methods capture fat mass reduction beyond total weight loss. Recent phase III trials of semaglutide and tirzepatide have underscored the utility of DXA and CT in quantifying fat loss and preserving lean mass. Selecting appropriate imaging modalities based on technical capabilities and regulatory considerations can improve the evaluation of obesity treatments and strengthen the design of anti-obesity drug trials.  \nKeywords: Obesity; Body composition analysis; Fat quantification; Anti-obesity drugs; Clinical trials  \nINTRODUCTION  \nThe global prevalence of obesity has steadily increased over recent decades, emerging as a major public health issue [1,2] . If the current trends persist, nearly 60% of the world’s population may become overweight or obese by 2030 [3] . In obesity, fat distribution, particularly the accumulation of visceral fat, plays a key role in increasing the risk of metabolic disorders, such as cardiovascular disease,  \nReceived: July 2, 2025 Revised: August 15, 2025  \nAccepted: August 28, 2025  \n*These authors contributed equally to this work.  \nCorresponding author: Hyo Jung Park, MD, PhD, Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea  \n• E-mail: [happyeahj@gmail.com](happyeahj@gmail.com)  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://creativecommons.org/licenses/by-nc/4.0](https://creativecommons.org/licenses/by-nc/4.0)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \ntype 2 diabetes, fatty liver, chronic kidney disease, and cancer [4-6]. Obesity also imposes a significant economic burden, accounting for up to 10% of healthcare expenditures in developed countries [7,8]. Individual-level interventions alone may be insufficient to address the escalating obesity issue; therefore, more comprehensive measures ","cbCaiow3k5yRib8w","https://ap.wps.com/l/cbCaiow3k5yRib8w","pdf",4050849,15,"English","# Introduction\n# Imaging in Adiposity and Anti-Obesity Drug Approval","[{\"question\":\"Why are imaging-based techniques important for evaluating obesity and adiposity?\",\"answer\":\"Traditional measures like BMI and waist circumference cannot reliably quantify fat mass and distinguish it from lean mass. Imaging can visualize internal structures and enable more comprehensive fat assessment and treatment monitoring.\"},{\"question\":\"How do DXA, CT, MRI, and BIA differ for fat quantification?\",\"answer\":\"DXA is cost-effective and suited for population-level screening, while CT and MRI provide higher precision, especially for visceral fat. BIA is practical and low-cost but limited by variability and lack of standardization.\"},{\"question\":\"How do imaging endpoints support approval of anti-obesity drugs?\",\"answer\":\"Regulatory agencies such as the U.S. FDA and Korean MFDS increasingly recommend imaging data in clinical trials. These endpoints capture fat mass reduction beyond total weight loss, helping establish that weight loss is primarily attributable to fat reduction.\"}]","Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs | PDF",1790745540,38]